Abstract:Abstract Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in the world. Metastasis, recurrence and therapy resistance remain major obstacles to the improvement of long-term survival and represent major causative factors contributing to the rising mortality rates and poor prognosis of HCC. Identification of key drivers important for clinical prognostic utility and elucidation of mechanisms involved in hepatocarcinogenesis is urgently needed to aid in the development of novel treatment modalities. To this end, we began our study with an analysis of a publicly gene expression dataset (GSE14520) comprising of transcriptomic profiles from a large cohort of human non-tumor liver and HCC clinical samples in hope to establish a prognostic gene signature associated with metastatic risk / recurrence status so to identify novel driver genes responsible for HCC development and progression. By this method, 4-hydroxyphenylpyruvate dioxygenase (HPD) was identified as a candidate tumor suppressor gene in HCC. HPD was found to be frequently down-regulated in primary HCC tumors as compared with peri-tumor liver tissues. Its expression negatively correlated with aggressive HCC pathological features, including tumor stage, metastasis, recurrence and survival. Notably, down-regulated HPD expression in HCC is in part a result of hypermethylation at the HPD promoter. The functional effect of HPD was then examined in HCC cells with or without HPD stably repressed or ectopically overexpressed. Upon knockdown of HPD, HCC cells displayed significantly enhanced abilities to form tumors, metastasize and confer sorafenib resistance in vitro and in vivo. Conversely, overexpression of HPD in HCC cells led to an opposing effect. Consistently, sorafenib-resistant HCC patient derived xenografts also displayed attenuated levels of HPD as compared with parental sorafenib-sensitive counterparts. Mechanistically, HPD down-regulation mediates aggressive cancer features in HCC through activation of an ERK and BCL-2 pro-survival signaling pathway, as evidenced by rescue experiments involving the ERK inhibitor U0126. Collectively, our findings suggest HPD down-regulation in HCC tumors to promote tumorigenicity, metastasis and sorafenib resistance through ERK / BCL-2 signaling activation and that HPD may represent a novel prognostic biomarker for HCC. Citation Format: Man Tong, Tin Lok Wong, Steve Tin-Chi Luk, Noélia Che, Kai Yau Wong, Tsun Ming Fung, Xin-Yuan Guan, Nikki P Lee, Yun-Fei Yuan, Terence K Lee, Stephanie Ma. Down-regulation of 4-hydroxyphenylpyruvate dioxygenate (HPD) contributes to the pathogenesis of hepatocellular carcinoma (HCC) through ERK / BCL-2 signalling activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1548. doi:10.1158/1538-7445.AM2017-1548

4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

6-Phosphogluconate Dehydrogenase Links Oxidative PPP, Lipogenesis and Tumour Growth by Inhibiting LKB1–AMPK Signalling

4-Hydroxyphenylpyruvate Dioxygenase-Like Protein Promotes Pancreatic Cancer Cell Progression and Is Associated With Glutamine-Mediated Redox Balance

PDHX acetylation facilitates tumor progression by disrupting PDC assembly and activating lactylation mediated gene expression

6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells

Tyrosine Metabolic Enzyme HPD is Decreased and Predicts Unfavorable Outcomes in Hepatocellular Carcinoma.

Abstract 1548: Down-regulation of 4-Hydroxyphenylpyruvate Dioxygenate (HPD) Contributes to the Pathogenesis of Hepatocellular Carcinoma (HCC) Through ERK / BCL-2 Signalling Activation

Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth

4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: A pan-cancer analysis

Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells.

Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.

HRD1 Elicitation of An Anti-Warburg Effect by Targeting PFKP to Inhibit Breast Cancer Growth and Progression

HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression.

Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer

Overexpression of Pyruvate Dehydrogenase Phosphatase 1 Promotes the Progression of Pancreatic Adenocarcinoma by Regulating Energy-Related AMPK/mTOR Signaling

Suppressed Expression of Ldhb Promotes Pancreatic Cancer Progression Via Inducing Glycolytic Phenotype

PHF12 regulates HDAC1 to promote tumorigenesis via EGFR/AKT signaling pathway in non-small cell lung cancer

Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion

6-Phosphogluconolactonase Promotes Hepatocellular Carcinogenesis by Activating Pentose Phosphate Pathway

Targeting Glucose-6-phosphate Dehydrogenase by 6-AN Induces ROS-mediated Autophagic Cell Death in Breast Cancer